Understanding the mechanisms and treatment options in cancer cachexia (Q38064733)

28 August 2017

1 reference

title

Understanding the mechanisms and treatment options in cancer cachexia (English)

1 reference

28 August 2017

Vickie Baracos

3

0 references

author name string

Kenneth Fearon

series ordinal

1

1 reference

28 August 2017

Jann Arends

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

4 December 2012

1 reference

Nature Reviews Clinical Oncology

28 August 2017

1 reference

28 August 2017

10

1 reference

28 August 2017

90-99

1 reference

28 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.209

28 August 2017

0 references

cites work

Definition and classification of cancer cachexia: an international consensus

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Chemotherapy and quality of life in NSCLC PS 2 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Risk factor paradox in wasting diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Would you buy a new tool to improve your practice?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Current concepts in cancer: effects of cancer and cancer treatment on the nutrition of the host

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Nutritional support of the cancer patient: issues and dilemmas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Cancer cachexia and fatigue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Anorexia and cachexia, asthenia, and lethargy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Fighting Over Food: Patient and Family Understanding of Cancer Cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Neurochemical and behavioral responses to inflammatory immune stressors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Cancer cachexia: mediators, signaling, and metabolic pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

P-selectin genotype is associated with the development of cancer cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Effect of 10 days of bed rest on skeletal muscle in healthy older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Aberrations in plasma phospholipid fatty acids in lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Choline: an essential nutrient for public health

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Glucocorticoids and muscle catabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Androgen therapy induces muscle protein anabolism in older women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

The views and practice of oncologists towards nutritional support in patients receiving chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

On appetite and its loss.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

The evolution of adjuvant therapy in the treatment of early-stage colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Energy expenditure and aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Physical exercise for cancer patients with advanced disease: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Are there any benefits of exercise training in cancer cachexia?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

The opposing effects of n-3 and n-6 fatty acids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Thalidomide in patients with cachexia due to terminal cancer: preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Clinical experience with thalidomide and lenalidomide in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

The effect of insulin on glucose and protein metabolism in the forearm of cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Targeting the myostatin signaling pathway to treat muscle wasting diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Evidence based practice guidelines for the nutritional management of cancer cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

Developing research programs in clinical and translational nutrition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.209

PI3 kinase regulation of skeletal muscle hypertrophy and atrophy

31 March 2020

1 reference

12 December 2020

Multimodal analgesia and intravenous nutrition preserves total body protein following major upper gastrointestinal surgery

1 reference

12 December 2020

Total parenteral nutrition in the surgical patient: a meta-analysis.

1 reference

12 December 2020

Hyperalimentation of the cancer patient with protein-calorie undernutrition

1 reference

12 December 2020

Inactivity amplifies the catabolic response of skeletal muscle to cortisol

1 reference

12 December 2020

Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.

1 reference

12 December 2020

Nutrition impact symptoms: key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment

1 reference

12 December 2020

Pulmonary rehabilitation: summary of an evidence-based guideline.

1 reference

12 December 2020

Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia.

1 reference

12 December 2020

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Effect of systemic hyperinsulinemia in cancer patients

1 reference

12 December 2020

10.1038/NRCLINONC.2012.209

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference